Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

CLINICAL TRIALS

Is representation enough or should we be targeting equitable inclusion?

Nature Reviews Clinical Oncology volume 19, pages 429–430 (2022)Cite this article

Subjects

To achieve health equity, we advocate for the overrepresentation of particular racial and ethnic minority groups so that analyses of group-specific treatment effects can be optimally powered. A paradigm shift is needed across multiple stakeholders, as well as in the engagement of community programmes, the role of investigators from racial and ethnic minority backgrounds and clinical trial regulations.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Owens-Walton, J., Williams, C., Rompré-Brodeur, A., Pinto, P. A. & Ball, M. W. Minority enrollment in phase ii and iii clinical trials in urologic oncology. J. Clin. Oncol. https://doi.org/10.1200/JCO.21.01885 (2022).

    Article  PubMed  Google Scholar 

  2. National Cancer Institute. Surveillance, Epidemiology, End Results Program. Number of Persons by Race and Hispanic Ethnicity for SEER Participants (2020 Census Data), https://seer.cancer.gov/registries/data.html (accessed 17 March 2022).

  3. Borno, H. T. et al. How current reporting practices may mask differences: a call for examining cancer-specific demographic enrollment patterns in cancer treatment clinical trials. Contemp. Clin. Trials Commun. 16, 100476 (2019).

    Article  Google Scholar 

  4. Anderson, A. & Griffith, D. M. Measuring the Trustworthiness of Health Care Organizations and Systems. Milbank Q. https://doi.org/10.1111/1468-0009.12564 (2022).

    Article  PubMed  Google Scholar 

  5. Jones, L. & Wells, K. Strategies for academic and clinician engagement in community-participatory partnered research. J. Am. Med. Assoc. 297, 407–410 (2007).

    Article  CAS  Google Scholar 

  6. NMF. NMF Diversity in Clinical Trials Research Program, https://nmfonline.org/scholarships-programs/diversity-in-research/clinical-trials-research/ (accessed 17 March 2022).

  7. Borno, H. T. et al. Implementation of a multisite financial reimbursement program in cancer clinical trials integrated with patient navigation: a pilot randomized clinical trial. JCO Oncol. Pract. https://doi.org/10.1200/OP.21.00328 (2022).

    Article  PubMed  PubMed Central  Google Scholar 

  8. Strauss, D. H., White, S. A. & Bierer, B. E. Justice, diversity, and research ethics review. Science 371, 1209–1211 (2021).

    Article  CAS  Google Scholar 

  9. McCaskill-Stevens, W., McKinney, M. M., Whitman, C. G. & Minasian, L. M. Increasing minority participation in cancer clinical trials: the minority-based community clinical oncology program experience. J. Clin. Oncol. 23, 5247–5254 (2005).

    Article  Google Scholar 

  10. Borno, H. T. et al. Integration of electronic pathology reporting with clinical trial matching for advanced prostate cancer. Urol Oncol. 39, 494.e7–494.e14 (2021).

    Article  Google Scholar 

Download references

Acknowledgements

Funding was provided in part by the Memorial Sloan Kettering Cancer Center Support Grant (P30 CA008748-50).

Author information

Authors and Affiliations

  1. Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA

    Scarlett Lin Gomez

  2. Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA

    Scarlett Lin Gomez

  3. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Chiaojung Jillian Tsai

Authors
  1. Scarlett Lin Gomez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chiaojung Jillian Tsai
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Scarlett Lin Gomez.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Related links

The North American Association of Central Cancer Registries: https://www.naaccr.org/

The NCI Community Oncology Research Program: https://ncorp.cancer.gov/

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gomez, S.L., Tsai, C.J. Is representation enough or should we be targeting equitable inclusion?. Nat Rev Clin Oncol 19, 429–430 (2022). https://doi.org/10.1038/s41571-022-00635-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41571-022-00635-z

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing